Pacira Pharma (PCRX) Misses Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Pacira BioSciences Reports First Quarter 2022 Financial Results
May 4, 2022 8:00 AM EDT-- First quarter revenue of $158 million, up 33% over prior year --
-- Strong topline performance delivers net income and significantly positive adjusted EBITDA --
-- Conference call today at 8:30 a.m. ET --
TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2022.
First Quarter 2022 Financial Highlights
Total revenues of $158.0... More